Does levodopa accelerate the pathologic process in Parkinson disease brain?

Parkkinen, L; O'Sullivan, S; Kuoppamaki, M; Collins, C; Kallis, C; Holton, J; Williams, D; Revesz, T; Lees, A

Journal article

Does levodopa accelerate the pathologic process in Parkinson disease brain?

Abstract:: Background: Several in vitro studies have suggested levodopa (L-dopa) to be toxic to dopaminergic neurons and that it can modulate the aggregation process of α-synuclein. We investigated the relationship between cumulative lifetime dose of L-dopa and nigral neuronal count and Lewy body (LB) pathology in Parkinson disease (PD).

Methods: Density of pigmented neurons was measured unilaterally in a single section of substantia nigra (SN) with delineation of the dorsal and ventral tiers in 96 cases of PD with well-documented clinical records relating to antiparkinsonian drug treatment. Cortical and nigral LB densities were determined using a morphometric approach.

Results: Mean lifetime dose of L-dopa correlated significantly (p < 0.001) with duration of PD in the entire study population (n = 96) and it was not possible to disentangle their individual effect. This was not the case in a subgroup analysis of younger onset patients with a longer duration of PD (n = 40) who showed no significant correlation between L-dopa and total SN neuronal density (p = 0.07), after adjustment for duration of illness. There was, however, a lower neuronal density in the ventral (p = 0.02) but not in the dorsal (p = 0.27) tier detected with the cumulative dose of L-dopa. We found no difference in L-dopa dose between Braak PD stages (p = 0.58). Furthermore, the subgroup analysis showed no relationship of L-dopa dose to either cortical (p = 0.47) or nigral (p = 0.48) LB density.

Conclusion: Chronic use of L-dopa in PD does not enhance progression of PD pathology as far as can be determined by our observations with SN neuronal counts and LB densities.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Parkkinen, L., O'Sullivan, S., Kuoppamaki, M., Collins, C., Kallis, C., Holton, J., Williams, D., Revesz, T., & Lees, A. (2011). Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology, 77(15), 1420–1426.

MLA Style

Parkkinen, L., et al. “Does Levodopa Accelerate the Pathologic Process in Parkinson Disease Brain?” Neurology, vol. 77, no. 15, American Academy of Neurology, 2011, pp. 1420–26.

Chicago Style

Parkkinen, L, S O'Sullivan, M Kuoppamaki, C Collins, C Kallis, J Holton, D Williams, T Revesz, and A Lees. 2011. “Does Levodopa Accelerate the Pathologic Process in Parkinson Disease Brain?” Neurology 77 (15): 1420–26.
Share
Print